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Abstract
Squamous cell carcinoma is the most common malignant oral tumor in cats. The late pre-
sentation is one of the factors contributing to the detrimental prognosis of this disease. The
immunohistochemical expression of the p53 tumor suppressor protein has been reported in
24% to 65% of feline oral squamous cell carcinomas, but no study has systematically evalu-
ated in this tumor the presence of p53 encoding gene (TP53) mutations. The aim of this ret-
rospective study was to determine whether p53 immunohistochemistry accurately reflects
the mutational status of the TP53 gene in feline oral squamous cell carcinoma. Additionally,
the prevalence of p53 dysregulation in feline oral squamous cell carcinoma was compared
with that of feline non-neoplastic oral mucosa, in order to investigate the relevance of these
dysregulations in cancer development. The association between p53 dysregulations and
exposure to environmental tobacco smoke and tumor characteristics was further assessed.
Twenty-six incisional biopsies of oral squamous cell carcinomas and 10 cases each of
lingual eosinophilic granuloma, chronic gingivostomatitis and normal oral mucosa were
included in the study. Eighteen squamous cell carcinomas (69%) expressed p53 and 18 had
mutations in exons 5–8 of TP53. The agreement between immunohistochemistry and muta-
tion analysis was 77%. None of non-neoplastic oral mucosa samples had a positive immu-
nohistochemical staining, while one case each of eosinophilic granuloma and chronic
gingivostomatitis harbored TP53 mutations. Unlike previously hypothesized, p53 dysregula-
tions were not associated with exposure to environmental tobacco smoke. These results
suggest an important role of p53 in feline oral tumorigenesis. Additionally, the immunohisto-
chemical detection of p53 expression appears to reflect the presence of TP53 mutations in
the majority of cases. It remains to be determined if the screening for p53 dysregulations,
alone or in association with other markers, can eventually contribute to the early detection of
this devastating disease.
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Introduction
Squamous cell carcinoma is the most common malignant tumor of the oral cavity in cats,
accounting for 60–70% of all oral malignancies. [1–3] Feline oral squamous cell carcinoma
(FOSCC) most frequently involves the lingual region and dentate jaws, and may appear either
as a necrotic ulcerative lesion or as a firm nodular swelling, generally associated with high local
invasiveness and early bone lysis. [2, 3] Although regional and distant metastases have been
reported, death most frequently occurs from complications associated with the primary tumor
before metastatic disease has an opportunity to become clinically relevant. [3, 4–6] Due to
location and rapid tumor progression, diagnosis is often late, and this largely limits the efficacy
of treatments, including surgery, radiation therapy and chemotherapy. Prognosis is poor for
the majority of cats, and, even with a multimodal therapeutic approach, the median survival
time rarely exceeds 12 months. [2, 7, 8]
The p53 protein, encoded by the TP53 oncosuppressor gene, counteracts the oncogenic
transformation and tumor growth by preventing the replication of genetically damaged cells.
[9, 10] Under unstressed physiologic conditions, the p53 protein has a half-life of 5–20 min in
most cell types and is maintained at a low level, therefore it is normally not detected by immu-
nohistochemical (IHC) methods [11]. Mutations of TP53 may induce conformational changes
that stabilize the protein, determining a nuclear accumulation of p53 that is detectable by IHC.
[12–14]
Somatic mutations in the TP53 gene are the most frequent alterations in human head and
neck squamous cell carcinoma (HNSCC), detected in up to 85% of cases, and have been
related to tobacco carcinogenesis. [15–17] In HNSCC, the IHC expression of p53 is also a
frequent finding and has been historically considered an indirect evidence of mutations,
although a disagreement between the two methods has been reported in up to 40% of cases.
[18, 19]
In FOSCC, the IHC expression of p53 has been reported in 24% to 65% of cases, [20–22]
and an association between p53 expression and exposure to household environmental tobacco
smoke (ETS) was hypothesized. [21] Although an anecdotal report exists of a TP53 mutation
in a FOSCC, [23] no study has systematically evaluated the presence of TP53 mutations in
these tumors, nor their association with IHC protein expression. Understanding the muta-
tional landscape of p53 in FOSCC may provide new insights to the molecular pathogenesis of
this disease, and allow meaningful comparisons with human oral cancer.
The aim of this study was to determine whether p53 IHC accurately reflects the mutational
status of the TP53 gene in FOSCC, and to investigate the relationship between p53 dysregula-
tions and ETS exposure in cats. Additionally, the prevalence of p53 expression and mutations
in FOSCC was compared with feline normal oral mucosa and oral inflammatory lesions, in
order to investigate the relevance of p53 dysregulation in cancer development.
Materials and methods
Ethics statement
This is a retrospective study on archived tissue samples of FOSCC. As the research did not
influence any therapeutic decision, approval by an ethics committee was not required.
However, all diagnostic and therapeutic procedures were performed in accordance with the
Public Health Service Policy on Humane Care and Use of Laboratory Animals.
All the examined samples were collected for diagnostic purposes as part of routine standard
care. Owners gave informed consent to the use of clinical data and stored biological samples
for teaching and research purposes.
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Case inclusion criteria and patient information
A retrospective survey was carried out on medical records of the Veterinary Hospital at the
Department of Veterinary Medical Sciences (University of Bologna, Italy) from 2010 to 2018,
in order to identify histologic samples of FOSCC and chronic oral inflammation. The histo-
logic sections were microscopically reviewed to confirm the diagnosis. All consecutive cases of
confirmed FOSCC were included, while 10 cases each of eosinophilic granuloma and chronic
gingivostomatitis were selected. In addition, 10 post-mortem histologic samples of feline oral
mucosa with normal histologic appearance were prospectively collected from cats with at least
7 years of age, deceased for causes unrelated to oral pathology. Samples were obtained from
the maxillary premolar gum.
Patient records were reviewed to collect demographic information and tumor location.
Cats’ owners were interviewed by e-mail or phone to collect information on ETS exposure,
which was graded as follows: no exposure (owners not smoking indoors or cats living exclu-
sively outdoors); mild exposure (1–5 cigarettes/day smoked indoors); moderate exposure (6–
10 cigarettes/day smoked indoors); intense exposure (>10 cigarettes/day smoked indoors).
The availability of this information was not among inclusion criteria.
Histology
All samples for histological examination had been fixed in 10% neutral-buffered formalin,
embedded in paraffin, sectioned at 4 μm and stained with hematoxylin and eosin (HE).
Histologic parameters evaluated for FOSCC included histologic subtype according to previ-
ously published criteria, [24, 25] histologic grade according to the Broders’ system (only for
the conventional histotype), [26] and mitotic count (MC). MC was assessed as the total num-
ber of mitotic figures in a 2.37 mm2 area (10 fields with a 40x objective and a 10x ocular with a
field number of 22 mm), according to the standards proposed by Meuten et al., 2016. [27] The
count was performed in 10 consecutive non-overlapping high-power fields (HPFs), starting
from an area of high mitotic activity. Fields with necrosis or inflammation were skipped. All
histologic evaluations were performed by consensus by two of the authors (AR1 and PDB).
Immunohistochemistry
Serial sections of FOSCC, eosinophilic granuloma, chronic gingivostomatitis and normal oral
mucosa were immunolabeled for p53 using a commercial mouse monoclonal antibody (Pab
240 clone, BD Biosciences, San Jose, California, USA) with validated reactivity in feline tissues.
[20, 22, 28]
Endogenous peroxidase activity was blocked by incubation for 10 min with 0.9% hydrogen
peroxide in phosphate buffered saline (PBS, pH 7.2). For antigen retrieval, slides were micro-
waved in citrate buffer (pH 6.0) for 4 cycles of 5 min, at 750 W. After 4 washes of 5 min each
with PBS containing 0.01% Tween 20 (p9416, Sigma Aldrich-Merck, Darmstadt, Germany)
and 0.01% non-fat dry milk, slides were pre-incubated with 20% normal goat serum diluted in
PBS containing 1% bovine serum albumin (BSA) for 20 min. Subsequently, slides were incu-
bated in a humid chamber with the primary antibody diluted 1:100 in PBS containing 1% BSA
for 80 min at room temperature. After another 4 washes of 5 min each with PBS containing
0.01% Tween 20 and 0.01% non-fat dry milk, binding sites of the primary antibody were iden-
tified using a biotinylated goat anti-mouse secondary antibody (Dako, Glostrup, Denmark)
diluted 1:100 in PBS containing 1% BSA, for 30 min at room temperature. Sections were then
incubated with a commercial streptavidin-biotin-peroxidase kit (Vectastain Elite ABC Kit,
Vector Laboratories, Burlingame, CA, USA) and 3,3-diaminobenzidine (DAB tablets,
p53 dysregulations in feline oral squamous cell carcinoma
PLOS ONE | https://doi.org/10.1371/journal.pone.0215621 April 18, 2019 3 / 13
Diagnostic BioSystems, Pleasanton, CA, USA) was used as chromogen. Counterstain was per-
formed with Papanicolaou’s hematoxylin.
A p53 positive FOSCC was used as positive control for the primary antibody. Negative con-
trols were obtained by omitting the primary antibody. Cases with at least 20% of p53-immuno-
reactive epithelial cells were considered positive, according to previous studies. [22, 28] Only
nuclear staining was regarded as specific. Interpretation of the p53 IHC staining was performed
by two of the authors (SS and AR2) without prior knowledge of TP53 mutational status.
TP53 mutation analysis
Mutation analysis was performed at the “M. Malpighi” Section of Anatomic Pathology and at
the Neurology Unit, IRCCS Institute of Neurological Sciences of Bologna, Department of Bio-
medical and Neuromotor Sciences, Bellaria Hospital, University of Bologna, Italy.
The TP53 mutational status of each included case of FOSCC, inflammatory lesions and nor-
mal oral mucosa was assessed by deep sequence analysis of exons 5 through 8, corresponding
to TP53 DNA binding domain.
Primers and chromosome coordinates are detailed in Table 1. DNA from 10 μm sections of
formalin-fixed and paraffin-embedded (FFPE) tissues (5 for each sample) was purified using
the MasterPure Complete DNA extraction kit (Epicentre, code MC85200, Madison, WI,
USA). If DNA amplification was not successful, the case was excluded from the study.
Locus-specific amplicon libraries were generated with the application of tagged primers
using multiplex PCR. The library preparation included two steps: a first PCR amplification for
target enrichment, and a second shorter amplification session (8 cycles) to allow the barcoding
of the template-specific amplicons obtained from the first amplification step. Barcoding was
performed by using Nextera index kit as previously described. [29] Following each PCR step,
the amplification products were purified using MagSi-NGSPREP (MagnaMedics, code
MDKT00010075, Geleen Netherlands) and quantified with the Quantus Fluorometer (Pro-
mega, code E6150, Milan, Italy).
Sequencing was conducted on MiSeq sequencer (Illumina, San Diego, CA, USA), according
to the manufacturer’s protocol.
Cases were classified as mutated when presenting one or more alterations in the nucleotide
sequence of the amplified exons of feline TP53, resulting in amino acid changes with negative
impact on the protein function according to PolyPhen-2, [30] and showing a variant allele fre-
quency (VAF) >10%.
Statistical analysis
Continuous data were tested for normality with the D’Agostino and Pearson omnibus normal-
ity test. Variables were summarized as mean ± standard deviation in case of normal distribu-
tion, or as median and range in case of non-normal distribution.
Table 1. TP53 primers and coordinates.
Exons Forward primer Reverse primer Genome coordinates
TP53 exon 5 AGTACTCCCCTCCCCTCAAC GCTCACCATCGCTACTGTCA Chrom E1, strand -: 2451253–2451447
Amplicon length: 194 bp
TP53 exon 6 ATTCCTCCCCGATTGCTCT CTCCCAGAGACCCCAGATG Chrom E1, strand -: 2451035–2451199
Amplicon length: 164 bp
Tp53 exon 7 ACTCGGCCGGATCTTCTCT CGGTAGCACGGGAGAGAGT Chrom E1, strand -: 2450673–2450857
Amplicon length: 184 bp
TP53 exon 8 TGCCTCCAGCTTCTGTCTTC CTCCCTGCCTCYTCTCGTC Chrom E1, strand -: 2450289–2450488
Amplicon length: 199 bp
https://doi.org/10.1371/journal.pone.0215621.t001
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The agreement between p53 immunohistochemical expression and TP53 mutation analysis
was assessed using the Cohen’s kappa coefficient (κ). [31] Additionally, the relationship
between p53 dysregulations (i.e., mutations or IHC expression) and the following variables
was investigated: exposure to ETS (yes/no), diagnosis (FOSCC, chronic inflammatory lesions,
normal oral mucosa), FOSCC location (dentate jaws, non-dentate mucosa, tongue), FOSCC
histotype (conventional vs. non-conventional), conventional FOSCC degree of differentiation
(well differentiated vs. moderately or poorly differentiated), and FOSCC MC. The distribution
of categorical variables between groups was assessed using either the χ2 test or Fisher’s exact
test; the distribution of quantitative variables between groups was assessed using either the
unpaired two-sample t-test or Mann-Whitney U test. The choice between tests depended on
the sample size and data distribution.
Analyses were carried out using a commercial software program (SPSS Statistics v19, IBM,
Armonk, NY, USA); the significance level was set at 0.05.
Results
The complete demographic, histological and molecular data of the cases in this study are pro-
vided in S1 and S2 Tables.
FOSCC
Twenty-six incisional biopsies of FOSCC met the inclusion criteria. Breeds included 22
Domestic shorthair (DSH) cats, 2 Chartreux, one Siamese and one Persian. There were 12 cas-
trated males and 14 spayed females. The median age was 14.5 years (range, 8–19). The infor-
mation on ETS was available for 24 cats, 6 of which (25%) were exposed (mild exposure, n = 2;
moderate exposure, n = 2; intense exposure, n = 2).
Tumors were located on mandibular gum (n = 12), maxillary gum (n = 6), tongue (n = 6),
vestibular mucosa (n = 1) and hard palate (n = 1).
Twenty-two FOSCC (84%) belonged to the conventional histotype, 11 of them (50%) were
well differentiated (grade 1 according to Broder’s grading system) and the remaining 11 were
moderately differentiated (grades 2 and 3). Well differentiated FOSCC were characterized by
neoplastic trabeculae with orderly progression from polyhedral, non-keratinized basal cells at
the periphery to large, polygonal, keratinized cells with prominent intercellular bridges at the
centers. Accumulations of amorphous to laminated keratin were frequently seen. Moderately
differentiated FOSCC were characterized by disordered maturation, tumor cells with less
eosinophilic cytoplasm and lack of evident intercellular bridges. Clusters of partially-kerati-
nized cells were prevalent over keratin accumulation.
The remaining FOSCC belonged to the acantholytic (n = 2; 8%) and spindle cell (n = 2; 8%)
histotypes.
The median MC was 13 in 10 HPF (range, 0–85).
Eighteen cases (69%) were positive for p53 IHC. The labelling was intense, with nuclear
localization and was either visible in all neoplastic cells (n = 9; 34.6%) or confined to the
periphery of the trabeculae (n = 9; 34.6%; Fig 1).
Nineteen mutations of TP53 were detected in 18 cases (69%); there were 16 missense muta-
tions, 1 nonsense mutation and 2 in frame deletions; all the examined exons were involved
(exon 5, n = 6; exon 6, n = 3; exon 7, n = 6; exon 8, n = 4).
Of the 18 FOSCC with IHC p53 expression, 3 cases with focal immunolabeling did not har-
bor TP53 mutations. Of the 18 tumors with mutated TP53, 3 were p53-negative; among these,
case 10 showed a PolyPhen2 score of 0.756, indicating only a possible damage; case 13 showed
p53 dysregulations in feline oral squamous cell carcinoma
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two mutations both with a PolyPhen2 score of 1.00, indicating full protein damage, with a 60%
and 27% VAF for p.Y155� and p.R206Q respectively. Finally, case 6 showed a single point
mutation in codon 207 (p.H207P) with a VAF of 13% and PolyPhen2 sore of 1.00; S1 Table).
Overall, there was agreement in 77% of FOSCC. The κ coefficient was 0.46 (P = 0.010), indicat-
ing a moderate agreement between p53 immunohistochemical expression and TP53 mutation
analysis.
Fig 1. Cat, oral mucosa. Representative examples of p53 immunohistochemistry. (A) Squamous cell carcinoma. Intense nuclear
labelling in all the neoplastic cells. (B) Squamous cell carcinoma. Intense nuclear labelling of the neoplastic cells at the periphery of
the trabeculae (focal positivity). (C) Eosinophilic granuloma and (D) chronic gingivostomatitis. Moderate cytoplasmic staining of the
inflammatory cells. (E) Chronic gingivostomatitis. Weak staining in less than 20% of nuclei in the basal and suprabasal layers of the
epithelium, which appears moderately hyperplastic. (F) Normal oral mucosa. Lack of positive staining. 200x magnification.
Haematoxylin counterstain.
https://doi.org/10.1371/journal.pone.0215621.g001
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Chronic inflammatory lesions
Cases of eosinophilic granuloma belonged to 10 DSH cats, 5 castrated males (50%) and 5
spayed females (50%). The median age was 9 years (range, 1–14). All lesions were located on
the tongue (dorsal aspect, n = 5; ventral aspect/frenulum, n = 4; lateral margin, n = 1).
Cats with chronic gingivostomatitis were 9 DSH and one Maine Coon; 7 (70%) were cas-
trated males and 3 (30%) spayed females. The median age was 11.5 years (range, 1–15). All
lesions were located on the dentate jaws (maxillary gum, n = 5; mandibular gum, n = 5).
The information on ETS was available for 16 out of 20 cats, 4 of which (25%; eosinophilic
granuloma, n = 2; chronic gingivostomatitis, n = 2) were exposed (mild exposure, n = 1; mod-
erate exposure, n = 1; intense exposure, n = 2).
Histologically, eosinophilic granulomas were characterized by a subepithelial infiltrate of
eosinophils and mononuclear cells, with the presence of "flame figures", consisting of deposits
of amorphous eosinophilic material surrounded by macrophages and multinucleated giant
cells. In chronic gingivostomatitis, the corium was expanded by variable amounts of lympho-
cytes and plasma cells, and covered by ulcerated to hyperplastic epithelium.
All inflammatory lesions were negative for p53 IHC, although showing a weak staining
in< 20% of epithelial cells, predominantly located in the basal layer of the hyperplastic areas.
A weak cytoplasmic staining was also observed in the subepithelial stroma, endothelial cells
and inflammatory cells.
TP53 missense mutations were detected in one eosinophilic granuloma (10%) and one
chronic gingivostomatitis (10%); mutations were located in exons 5 (n = 1), 6 (n = 1) and 7
(n = 2; S2 Table).
Normal oral mucosa
The 10 normal oral mucosa samples belonged to 9 DSH and 1 Chartreux; 7 males (70%; 6 cas-
trated) and 3 spayed females (30%). The median age was 11 (range, 7–17). The causes of death
included cardiomyopathy (n = 3), chronic kidney disease (n = 2), intestinal lymphoma (n = 2),
hemorrhagic cystitis (n = 1), pulmonary carcinoma (n = 1), and meningioma (n = 1).
Three cats (30%) were exposed to ETS (mild exposure, n = 2; moderate exposure, n = 1).
None of the samples was positive for p53 IHC, and no TP53 mutation was detected (S2
Table).
Statistical analysis of p53 dysregulations
Overall, the agreement between p53 immunohistochemistry and mutation analysis was 86%.
The κ coefficient was 0.68 (P < 0.001), indicating a substantial agreement between p53
immunohistochemical expression and TP53 mutation analysis. Both p53 IHC overexpression
and TP53 mutations were significantly more frequent in FOSCC, and mutated cases had a sig-
nificantly lower MC (Tables 2 and 3). There was no statistical relationship between p53 dysre-
gulations and the other evaluated variables, including exposure to ETS (Tables 2 and 3).
Discussion
There are many similarities at both clinical and molecular level between HNSCC and FOSCC,
which has led to the proposal that FOSCC may serve as a spontaneous model for human dis-
ease. [22, 32, 33]
Herein, we provide further evidence to this hypothesis, by demonstrating in FOSCC a high
prevalence (69%) of mutations in the DNA binding domain of TP53. This is also the most fre-
quent site of somatic genomic alterations in HNSCC, and the most important region for
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Table 2. Relationship between p53 immunohistochemical expression and other clinicopathological variables in 56 histological samples of feline oral mucosa.
Variable p53 not expressed p53 expressed P
ETS (n = 50) (4 missing) (2 missing) 0.508
exposed 10 (29%) 3 (19%)
not exposed 24 (71%) 13 (81%)
Diagnosis (n = 56) <0.001
FOSCC 8 (21%) 18 (100%)
chronic inflammatory lesions 20 (53%) 0 (0%)
normal oral mucosa 10 (26%) 0 (0%)
FOSCC location (n = 26) 0.657
dentate jaws 6 (75%) 12 (67%)
non-dentate mucosa 1 (13%) 1 (6%)
tongue 1 (13%) 5 (28%)
FOSCC histotype (n = 26) 0.563
conventional 6 (75%) 16 (89%)
non conventional 2 (25%) 2 (11%)
Conventional FOSCC degree of differentiation (n = 22) 0.635
well differentiated 2 (33%) 9 (56%)
moderately/poorly differentiated 4 (67%) 7 (44%)
FOSCC MC (n = 26)
(median, range)
16 [6–85] 11 [0–81] 0.388
Abbreviations: ETS, environmental tobacco smoke; FOSCC, feline oral squamous cell carcinoma; MC, mitotic count.
https://doi.org/10.1371/journal.pone.0215621.t002
Table 3. Relationship between TP53 mutations and other clinicopathological variables in 56 histological samples of feline oral mucosa.
Variable TP53 wild-type TP53 mutated P
ETS (n = 50) (3 missing) (3 missing) >0.999
exposed 9 (27%) 4 (24%)
not exposed 24 (73%) 13 (76%)
Diagnosis (n = 56) <0.001
FOSCC 8 (22%) 18 (90%)
chronic inflammatory lesions 18 (50%) 2 (10%)
normal oral mucosa 10 (28%) 0 (0%)
FOSCC location (n = 26) 0.283
dentate jaws 4 (50%) 14 (78%)
non-dentate mucosa 1 (13%) 1 (6%)
tongue 3 (38%) 3 (17%)
FOSCC histotype (n = 26) 0.563
conventional 6 (75%) 16 (89%)
non conventional 2 (25%) 2 (11%)
Conventional FOSCC degree of differentiation (n = 22) 0.635
well differentiated 2 (33%) 9 (56%)
moderately or poorly differentiated 4 (67%) 7 (44%)
FOSCC MC (n = 26) (median, range) 16.5 [10–85] 7.5 [0–79] 0.034
Abbreviations: ETS, environmental tobacco smoke; FOSCC, feline oral squamous cell carcinoma; MC, mitotic count.
https://doi.org/10.1371/journal.pone.0215621.t003
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folding and stabilization of the tertiary structure of the protein, suggesting the importance of
the loss of function of the p53 pathway in the development and progression of oral cancer in
both species. [19, 34]
While cells with functional p53 respond to DNA damage by undergoing cell-cycle arrest,
DNA repair or apoptosis, cells lacking functional p53 may continue to divide and accumulate
genetic damages, thus leading to a potential malignant transformation. Although p53 mutants
can be classified by their effect on protein structure, it is currently not possible to predict pre-
cisely how a particular mutation impairs function [34].
In most cases, mutations were also associated with p53 IHC expression, as confirmed by an
agreement of 77%. Predictably, discordant results were obtained, including 3 IHC positive
cases with no TP53 mutation and 3 IHC negative cases harboring TP53 mutations. In humans,
positive results in p53 IHC have formerly been interpreted as indicating inactivation of the
TP53 gene, based on the knowledge that the half-life of the wild-type protein is too short to
permit detection, whereas the mutant protein is more stable. However, the role of p53 immu-
nostaining as a surrogate marker of TP53 gene alterations has been downgraded over time.
[19, 35] Although IHC is rapid, relatively inexpensive, and widely available to most diagnostic
laboratories, a number of biological and technical factors may contribute to limit its correla-
tion with genetic analysis. p53 expression in the absence of detectable mutations may be
related to the presence of genetic alterations outside the DNA binding domain; alternatively,
post-transcriptional protein accumulation may result from aberrant degradation or induction
by genotoxic insults; whereas stabilization can be mediated by cellular and transforming viral
proteins. [19, 36, 37] In humans, papillomavirus (PV) E6 protein may produce a similar effect;
however, while PV DNA sequences have been detected in a small proportion of FOSCC, there
is currently no evidence that PV has a role in the development of oral cancer in cats. [38]
Absence of IHC positivity in mutated FOSCC could be due to mutations that do not result
in protein stabilization, undetectable truncated proteins or deletions that inhibit transcription
altogether. Furthermore, mutations which render a conformational change not recognized by
the primary antibody will generate false negatives, as may result for cases 6, 10, and 13. [35, 39]
In case 13 the simultaneous presence of two damaging mutations (p.Y155�; p.R206Q) with
high VAF and high Polyphen2 score may justify the loss of p53 staining. The same immunos-
taining behavior was detected for case 6, harboring a damaging mutation in p.H207P, very
close to p.R206Q. The low VAF (13%) and probably the region involved may be the cause of
undetectable IHC signal. Finally, case 10 showed a Polyphen2 score of 0.756, indicating only a
possible protein damage, probably not enough to be recognized by the p53 Pab 240 clone.
In addition to these biological mechanisms, technical limitations may also give account for
discrepancies between p53 IHC and mutational analysis, including the choice of the antibody
and of the thresholds for positive p53 staining and variant allele frequency. [36] Numerous
monoclonal antibodies are available for the IHC analysis of human p53 protein, and the sensi-
tivity of the immunostaining can be refined by using different clones simultaneously. Cur-
rently, the p53 antibodies with known immunoreactivity in feline tissues are PAb240 and CM-
1. A study on different canine neoplasms obtained the highest percentage of positive cases
with the polyclonal antibody CM-1; [40] nevertheless, in this study the PAb 240 clone was pre-
ferred, because it has been reported to produce less background staining than CM-1 and to
recognize more specifically the mutant epitopes of p53. [20, 22, 28, 40, 41] Additional technical
issues may relate to the formalin fixation process, which on the one hand might limit the
immunoreactivity of samples and on the other hand induce excessive DNA fragmentation.
This study reports a significantly higher prevalence of p53 dysregulation in FOSCC com-
pared with non-neoplastic oral lesions, further supporting a role of p53 in oral tumorigenesis.
This apparent specificity also makes p53 a potential candidate for investigation as a diagnostic
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biomarker. In humans, p53 mutations are important determinants of the malignant potential
of oral lesions and have been detected in the saliva and blood of HNSCC-bearing patients. [19,
42, 43] In cats, no oral lesions of confirmed or presumed preneoplastic significance have so far
been identified, and early neoplastic disease may be hard to differentiate from other chronic
inflammatory or proliferative lesion of the oral mucosa. Dental disease with associated peri-
odontitis, gingivitis and gingival hyperplasia is a common finding in elderly cats, and idio-
pathic ulcerative lesions belonging to the feline eosinophilic granuloma complex and
mimicking FOSCC may occur on the tongue or frenulum. [3] Even histologically, the early dis-
tinction between neoplastic and inflammatory disorders can be challenging: squamous cell
carcinomas are frequently accompanied by an inflammatory response, due to the presence of
epithelial ulceration and keratin production. In turn, chronic stomatitis may induce hyper-
plastic-dysplastic changes of the mucosa that can hardly be differentiated from early neoplastic
transformation.
Since the early detection of FOSCC is the only weapon currently available to effectively
fight this disease, further studies are worth to assess the diagnostic potential of p53, alone or
in association with other molecular markers. In this scenario, it is interesting to speculate
whether the two mutations with no concurrent IHC expression found in inflammatory lesions
should be regarded as nonspecific findings or as the result of an early inflammation-driven
carcinogenesis. Considering the frequency of chronic stomatitis in geriatric cats, it can be diffi-
cult to estimate how reliable is the risk of a neoplastic transformation of these lesions.
The pathogenesis of FOSCC is not well characterized, but exposure to tobacco smoke has
been postulated as a potential risk factor, among others, potentially due to the grooming habits
of cats increasing the oral dose of environmental carcinogens. [44] Furthermore, in one study,
tumors from cats exposed to ETS were 4.5 times more likely to overexpress p53 than were
tumors from unexposed cats, although this association was not statistically significant. [21] In
the present study, exposure to tobacco smoke was unfrequently observed in cats with SCC,
being reported in 6 out of 24 cases, and was not associated with either p53 expression or TP53
mutations. While not excluding the carcinogenetic effect of ETS in FOSCC, these results let us
hypothesize that other factors may have triggered the dysregulation of the p53 pathway in
these cats.
The main limits of this study are the small number of cases and its retrospective design, with
consequent lack of standardized therapy protocols. This also impairs any consideration on the
biologic behavior of mutated tumors and, ultimately, on the prognostic significance of p53.
Conclusions
These results suggest an important role of p53 in feline oral tumorigenesis. This is supported
by a significantly higher prevalence of p53 dysregulation in FOSCC compared with normal
oral mucosa and inflammatory lesions. Additionally, the IHC detection of p53 expression
appears to reflect the presence of p53 mutations in the majority of cases. It remains to be deter-
mined if the screening for p53 dysregulations, alone or in association with other markers, may
contribute to the early detection of this detrimental disease, and eventually help to make it
more curable.
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